FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335008365> ?p ?o ?g. }

• W2335008365 endingPage "19" @default.
• W2335008365 startingPage "15" @default.
• W2335008365 abstract "<b>Aim of the study:</b> To investigate the effectiveness and safety of etanercept (ETA) treatment in patients with active rheumatoid arthritis (RA) and ankylosing spondylitis (AS) enrolled in the national therapeutic program.<br /> <b>Material and methods:</b> The study was conducted in 55 adult patients with active RA (DAS28 > 5.8) and 33 adult patients with active AS (BASDAI > 7) who were enrolled in the ETA national therapeutic program as a first (40 RA patients) or second (15 RA patients) line biological therapy. The period of observation of RA patients lasted from 3 months to 9 years, whereas in AS patients it lasted from 1 to 30 months. The safety; rate of long-term remissions and primary or secondary ineffectiveness of ETA treatment were analyzed.<br /> <b>Results</b>: Permanent remission (over 12 months without biological therapy) occurred in a similar percentage of RA patients (5–9%) and AS patients (3–9%). There were 7 non-responders (12.7%) to the initial treatment with ETA in a group of RA patients and 3 (9%) in AS patients (NS). Secondary ineffectiveness of ETA therapy was observed in 19 (34.5%) RA patients and in 2 (6.1%) AS patients. Side effects (infections and allergic skin reactions) were relatively rare, mainly at the beginning of therapy.<br /> <b>Conclusions: </b>We conclude that ETA treatment is a safe and effective form of therapy in patients with active, long-term RA previously treated with various DMARDs, and in patients with active form of AS. Primary ineffectiveness of ETA therapy is relatively rare in RA and AS patients. On the other hand, the secondary ineffectiveness of therapy in RA patients is the reason for its discontinuation in about one-third of patients after ca. 28 months of treatment." @default.
• W2335008365 created "2016-06-24" @default.
• W2335008365 creator A5001420714 @default.
• W2335008365 creator A5025955879 @default.
• W2335008365 creator A5077144012 @default.
• W2335008365 date "2013-03-05" @default.
• W2335008365 modified "2023-10-01" @default.
• W2335008365 title "Etanercept in a therapeutic program for the treatment of rheumatoid arthritis and ankylosing spondylitis – 7 years’ personal experience" @default.
• W2335008365 cites W1761300068 @default.
• W2335008365 cites W1989549387 @default.
• W2335008365 cites W2029629958 @default.
• W2335008365 cites W2056486682 @default.
• W2335008365 cites W2076071844 @default.
• W2335008365 cites W2140219205 @default.
• W2335008365 cites W2155109530 @default.
• W2335008365 cites W2161584208 @default.
• W2335008365 cites W2162145337 @default.
• W2335008365 cites W2319791162 @default.
• W2335008365 cites W3006080604 @default.
• W2335008365 doi "https://doi.org/10.5114/reum.2013.33388" @default.
• W2335008365 hasPublicationYear "2013" @default.
• W2335008365 type Work @default.
• W2335008365 sameAs 2335008365 @default.
• W2335008365 citedByCount "0" @default.
• W2335008365 crossrefType "journal-article" @default.
• W2335008365 hasAuthorship W2335008365A5001420714 @default.
• W2335008365 hasAuthorship W2335008365A5025955879 @default.
• W2335008365 hasAuthorship W2335008365A5077144012 @default.
• W2335008365 hasBestOaLocation W23350083651 @default.
• W2335008365 hasConcept C102652120 @default.
• W2335008365 hasConcept C126322002 @default.
• W2335008365 hasConcept C2776260265 @default.
• W2335008365 hasConcept C2777226972 @default.
• W2335008365 hasConcept C2777402515 @default.
• W2335008365 hasConcept C2777453003 @default.
• W2335008365 hasConcept C2777575956 @default.
• W2335008365 hasConcept C71924100 @default.
• W2335008365 hasConcept C90924648 @default.
• W2335008365 hasConceptScore W2335008365C102652120 @default.
• W2335008365 hasConceptScore W2335008365C126322002 @default.
• W2335008365 hasConceptScore W2335008365C2776260265 @default.
• W2335008365 hasConceptScore W2335008365C2777226972 @default.
• W2335008365 hasConceptScore W2335008365C2777402515 @default.
• W2335008365 hasConceptScore W2335008365C2777453003 @default.
• W2335008365 hasConceptScore W2335008365C2777575956 @default.
• W2335008365 hasConceptScore W2335008365C71924100 @default.
• W2335008365 hasConceptScore W2335008365C90924648 @default.
• W2335008365 hasIssue "1" @default.
• W2335008365 hasLocation W23350083651 @default.
• W2335008365 hasOpenAccess W2335008365 @default.
• W2335008365 hasPrimaryLocation W23350083651 @default.
• W2335008365 hasRelatedWork W2052900499 @default.
• W2335008365 hasRelatedWork W2072412214 @default.
• W2335008365 hasRelatedWork W2111965497 @default.
• W2335008365 hasRelatedWork W2147166948 @default.
• W2335008365 hasRelatedWork W2148305943 @default.
• W2335008365 hasRelatedWork W2171255147 @default.
• W2335008365 hasRelatedWork W2376526565 @default.
• W2335008365 hasRelatedWork W2391787653 @default.
• W2335008365 hasRelatedWork W2956648588 @default.
• W2335008365 hasRelatedWork W4235629817 @default.
• W2335008365 hasVolume "51" @default.
• W2335008365 isParatext "false" @default.
• W2335008365 isRetracted "false" @default.
• W2335008365 magId "2335008365" @default.
• W2335008365 workType "article" @default.